<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Mousnier A</submitter><funding>Cancer Research UK</funding><funding>Medical Research Council</funding><funding>Biotechnology and Biological Sciences Research Council</funding><pagination>599-606</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC6015761</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>10(6)</volume><pubmed_abstract>Rhinoviruses (RVs) are the pathogens most often responsible for the common cold, and are a frequent cause of exacerbations in asthma, chronic obstructive pulmonary disease and cystic fibrosis. Here we report the discovery of IMP-1088, a picomolar dual inhibitor of the human N-myristoyltransferases NMT1 and NMT2, and use it to demonstrate that pharmacological inhibition of host-cell N-myristoylation rapidly and completely prevents rhinoviral replication without inducing cytotoxicity. The identification of cooperative binding between weak-binding fragments led to rapid inhibitor optimization through fragment reconstruction, structure-guided fragment linking and conformational control over linker geometry. We show that inhibition of the co-translational myristoylation of a specific virus-enco</pubmed_abstract><journal>Nature chemistry</journal><pubmed_title>Fragment-derived inhibitors of human N-myristoyltransferase block capsid assembly and replication of the common cold virus.</pubmed_title><pmcid>PMC6015761</pmcid><funding_grant_id>MC_PC_14100</funding_grant_id><funding_grant_id>20183</funding_grant_id><funding_grant_id>BBS/E/I/00007034</funding_grant_id><funding_grant_id>G1000758</funding_grant_id><funding_grant_id>G1100238</funding_grant_id><funding_grant_id>G0900278</funding_grant_id><pubmed_authors>Brannigan JA</pubmed_authors><pubmed_authors>Johnston SL</pubmed_authors><pubmed_authors>Tuthill TJ</pubmed_authors><pubmed_authors>Hopkins-Navratilova I</pubmed_authors><pubmed_authors>Newman J</pubmed_authors><pubmed_authors>Mousnier A</pubmed_authors><pubmed_authors>Asfor AS</pubmed_authors><pubmed_authors>Swieboda DP</pubmed_authors><pubmed_authors>Guedan A</pubmed_authors><pubmed_authors>Leatherbarrow RJ</pubmed_authors><pubmed_authors>Solari R</pubmed_authors><pubmed_authors>Tate EW</pubmed_authors><pubmed_authors>Bell AS</pubmed_authors><pubmed_authors>Hutton JA</pubmed_authors><pubmed_authors>Perez-Dorado I</pubmed_authors><pubmed_authors>Morales-Sanfrutos J</pubmed_authors><pubmed_authors>Wilkinson AJ</pubmed_authors><pubmed_authors>Ritzefeld M</pubmed_authors><pubmed_authors>Robinson SW</pubmed_authors></additional><is_claimable>false</is_claimable><name>Fragment-derived inhibitors of human N-myristoyltransferase block capsid assembly and replication of the common cold virus.</name><description>Rhinoviruses (RVs) are the pathogens most often responsible for the common cold, and are a frequent cause of exacerbations in asthma, chronic obstructive pulmonary disease and cystic fibrosis. Here we report the discovery of IMP-1088, a picomolar dual inhibitor of the human N-myristoyltransferases NMT1 and NMT2, and use it to demonstrate that pharmacological inhibition of host-cell N-myristoylation rapidly and completely prevents rhinoviral replication without inducing cytotoxicity. The identification of cooperative binding between weak-binding fragments led to rapid inhibitor optimization through fragment reconstruction, structure-guided fragment linking and conformational control over linker geometry. We show that inhibition of the co-translational myristoylation of a specific virus-enco</description><dates><release>2018-01-01T00:00:00Z</release><publication>2018 Jun</publication><modification>2026-05-04T07:50:49.737Z</modification><creation>2019-03-27T00:07:03Z</creation></dates><accession>S-EPMC6015761</accession><cross_references><pubmed>29760414</pubmed><doi>10.1038/s41557-018-0039-2</doi></cross_references></HashMap>